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Abstract
With the advance of genome-wide association studies and newly identified SNP (single-nucleotide polymorphism)
associations with complex disease, important discoveries have emerged focusing not only on individual genes but on
disease-associated pathways and gene sets. The authors used prospective myocardial infarction case-control
studies nested in the Nurses’ Health and Health Professionals Follow-Up Studies to investigate genetic variants
associated with myocardial infarction or LDL, HDL, triglycerides, adiponectin and apolipoprotein B (apoB). Using
these case-control studies to illustrate an integrative systems biology approach, the authors applied SNP set
enrichment analysis to identify gene sets where expression SNPs representing genes from these sets show
enrichment in their association with endpoints of interest. The authors also explored an aggregate score approach.
While power limited one’s ability to detect significance for association of individual loci with myocardial infarction, the
authors found significance for loci associated with LDL, HDL, apoB and triglycerides, replicating previous
observations. Applying SNP set enrichment analysis and risk score methods, the authors also found significance for
three gene sets and for aggregate scores associated with myocardial infarction as well as for loci-related to
cardiovascular risk factors, supporting the use of these methods in practice.
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Introduction
The traditional risk factors for myocardial infarction (MI)
include age, plasma lipid concentrations, blood pressure, use
of tobacco, and presence of type 2 diabetes mellitus. Family
history has also been established as an important risk factor for
MI, and is included in some risk scores [1]. While lifestyle
clearly plays a role in these risk factors, a large proportion of
the inter-individual variability in plasma lipid concentrations is
due to inherited factors [2-6]. Premature MI appears to have a
particularly strong genetic component independent of
established risk factors, and individuals having at least one
parent with premature cardiovascular disease (age of onset
<55 years in men, <65 years in women) have significantly
increased risk of a cardiovascular event [7].
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These observations have motivated investigators to
undertake a variety of studies to identify genes responsible for
the heritability of MI and cardiovascular risk factors. For several
decades, linkage analyses and candidate gene studies
investigated genes responsible for the heritability of
cardiovascular risk and successfully identified a handful of loci
unequivocally linked to MI, as well as several additional loci
with a weaker level of evidence.
More recently, the emergence of genome-wide association
(GWA) arrays have made it possible to perform genome-scale
screens for common DNA sequence variants associated with
phenotypes of interest including coronary artery disease and
MI [8-10]. Genome-wide association studies (GWAS) involving
up to 100,000 individuals of European ancestry have identified
>90 genetic loci contributing to inter-individual variation in
plasma lipid concentrations [11]. Many of these loci harbored
genes previously known to influence plasma lipid
concentrations. Knowledge of the new sequence variants that
confer risk has the potential to illuminate causal biologic
pathways in humans and help appropriately target diagnosis
and treatment [12].
Whereas most prior GWA studies of coronary heart disease
(CHD) have been cross-sectional, we performed GWAS using
the established prospective MI case-control studies of the
Nurses’ Health Study (NHS) and Health Professionals Follow-
Up Study (HPFS) cohort to identify common genetic variants
that associate with MI, cardiovascular disease biomarkers and
lipids. The use of prospective studies avoids survival bias
which can confound cross-sectional studies. With integrative
analysis approaches, we used expression SNPs (eSNPs),
transcriptional networks and expression profiling signatures to
explore explanatory relationships between genetic variants
identified and disease phenotype.
Materials and Methods
Study Design and Samples
Details of the NHS and HPFS cohorts have been described
previously [13,14]. Briefly, the NHS was established in 1976
when 121,700 female registered nurses aged 30–55 years and
residing in 11 US states completed a mailed questionnaire on
their medical history and lifestyle. The lifestyle factors,
including smoking, menopausal status and postmenopausal
hormone therapy and body weight, have been updated by
validated questionnaires every 2 years. A total of 32,826
women provided blood samples between 1989 and 1990. The
HPFS is a prospective cohort study of 51,529 US male health
professionals aged 40–75 years at study initiation in 1986.
Information about health and disease is assessed biennially by
a self-administered questionnaire. Between 1993 and 1999,
18,159 men provided blood samples. Participants from both
cohorts underwent local phlebotomy and returned samples to
our laboratory via overnight courier. Upon arrival, whole blood
samples were centrifuged and stored in cryotubes as plasma,
buffy coat, and red blood cells in the vapor phase of liquid
nitrogen freezers. DNA was extracted from the buffy coat
fraction of centrifuged blood with the QLAmp Blood Kit
(Qiagen, Chatsworth, California).
NHS and HPFS participants for the current study were those
with a blood sample in the nested case–control studies of
incident CHD, defined as non-fatal MI or fatal CHD. In the
NHS, 474 women free of cardiovascular disease or cancer in
1990 and 454 men in HPFS free of cardiovascular disease in
1994 developed incident CHD prior to June 2004. For each
incident case of CHD, 2 men or women who were free of
cardiovascular disease were randomly selected matching on
age (in 5-year increments), smoking (in 5 categories), and
month of blood return using risk-set sampling [15]. In the NHS,
matching criteria also included fasting status and reported
problems with blood sampling.
Ethics Statement
The present study was approved by the institutional review
board of the Brigham and Women's Hospital and the Human
Subjects Committee Review Board of Harvard School of Public
Health. All documents sent to participants have been approved
by the ethics committee.
We wrote to participants who reported incident CHD on the
follow-up questionnaires to confirm the report and request
permission to review medical records. Participants, or the next
of kin in the case of deceased participants, provided implied
written consent by the return of the mailed questionnaires.
However, further consent to review medical records was
through signed written consent. To document the process,
upon reporting an incident MI, participants were recontacted by
mail to confirm the report and to obtain written consent to
review medical records. We also sought medical records for
deceased participants, whose deaths were identified by
families and postal officials and through the National Death
Index. Physicians blinded to the participant’s questionnaire
reports reviewed all medical records. Cases were identified
primarily through review of medical records, as previously
described [14,16].
Genotyping and Quality Control
Genotyping was done using the Affymetrix SNP 6.0 array
and the Birdseed calling algorithm [17]. Genotypic data for a
total of 1330 HPFS samples (98%) passed laboratory technical
quality control criteria. Likewise, 96% of the NHS samples were
successfully genotyped. A subset of 312 NHS samples were
not genotyped together with the remaining CHD case-control
set as they overlapped with previous GWA studies of breast
cancer (Illumina 550) and type 2 diabetes (Affymetrix 6.0).
These samples were quality controlled as part of the earlier
GWAS (leaving n=272 samples with available data) and SNPs,
also present on the Affymetrix 6.0 platform, were subsequently
merged with the CHD data, after removing samples with the
following criteria: 1) accidental duplicates as identified by
pairwise identity-by descent; 2) samples identified as siblings;
3) discordant genotypic and phenotypic sex; and 4) sample call
rate <98%. Population structure was investigated by principal
component analysis. We used a set of 12,021 SNPs selected
to have very low levels of linkage disequilibrium and minor
allele frequency >0.05 in Caucasians [18]. Study subjects
passing quality control were analyzed together with a set of
209 HapMap II founders (59 CEU, 60 YRI, 45 JPT and 45
Integrative Genomics of Incident MI in NHS, HPFS
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CHB). Subjects within the means of the first and second
principal components [mean (SD) = 3] among self-described
Caucasians were classified as having primarily European
ancestry. Due to very few samples with substantial evidence of
non-European genetic ancestry, these samples were excluded
from subsequent analysis (n=24). SNPs that were
monomorphic, had a missing call rate ≥2%, a Hardy-Weinberg
Equilibrium p-value <1×10-4, or a minor allele frequency <0.02
were excluded, leaving a total of 724,881 SNPs that passed
quality control in HPFS and 721,316 in NHS for analysis of
called genotypes. Imputation of ~2.5 million SNPs was
performed using MACH software (v1.0.16) with HapMap CEU
phased II data (Release 22) as the reference panel.
Statistical Analysis
We performed unconditional logistic regression to analyze
the association between each assayed or imputed SNP and
incident CHD risk using an additive genetic model.
Unconditional regression was used because some of the
original matches were broken when informed consent had to
be obtained a second time. NHS and HPFS were examined
separately. The genomic inflation factor was adjusted by
genomic control methods. To control for potential confounding
by population stratification, we performed further analyses by
including the top principal components of genetic variation
chosen for each study in the models. Adjusting for the top three
and four principal components for NHS and HPFS,
respectively, made no material difference to the GWA results.
We used two meta-analytic methods to summarize the
statistical evidence for each SNP. We combined odds ratios for
a given reference allele on a logarithmic scale weighted by the
inverse of their variances using a fixed-effects model. We also
combined evidence for association solely on the basis of
signed p-values weighted by sample size. In brief, we
converted the two-sided p-value to a z-statistic and assigned a
sign to reflect the direction of the association given the
reference allele. Each z-score was then weighted with the
squared weights summing to 1, with sample-specific weights
being proportional to the square root of the effective number of
individuals in the sample.
All analyses were implemented using R (version 2.12).
SSEA
A SNP set enrichment (SSEA) test [19,20] was applied in an
attempt to identify underlying biological signals within the many
suggestive associations observed for MI in this dataset. Briefly,
more than 100 gene sets derived from mRNA profiling
signatures, gene expression networks and other sources
relevant to dyslipidemia and cardiovascular disease were
assembled (Table S1 and Table S2). Each gene set was
sequentially tested against the associations identified for the
phenotype of interest (Figure 1). For each gene set, multiple
eSNPs representing the genes in that gene set were tested as
a group for association to the trait of interest using a
Kolmogorov-Smirnov test. Gene sets corresponding to Kegg
pathways were also tested for the phenotype of MI.
Testing for Gene Environment Interaction
Taking advantage of the rich environmental data captured in
this cohort, we examined gene-environment interactions for
HDL, apoB, LDL, smoking, and alcohol in relation to incident MI
using both linear and non-linear terms. Given the additional
tests, although not independent, a conservative Bonferroni
threshold of p<1E-9 was considered for genome wide
significance We also constructed a two degree of freedom test
for main and interaction effects in the context of nested models.
The test is essentially equivalent to that proposed by Kraft et al.
[21]. By comparing a model with both main effects and the
interaction between the gene and the environmental factor to
one with only the main effects, a likelihood ratio test was
formed to screen (1) SNPs which may have significant main or
interaction effects, and (2) SNPs may only show significant
associations when interaction is considered. Both of these
models were fit using the continuous linear and non-linear
variable for the trait of interest (alcohol, HDL, total cholesterol,
apoB). We constructed four sets of logit models, and tested the
SNP by environmental interactions by comparing the full model
vs the null model in each set after adjusting for age, smoking
and principal components. The four models differed by whether
the environmental factor was fit using a polynomial spline
function with three degrees of freedom or a continuous linear
function (methods S1). Finally, we reported significant
interactions in any of those models.
Predicting MI Risk using SNPs Underlying Lipids and
Other Risk Factors
A genotype risk score similar to that of Purcell et al. [22] was
applied to evaluate whether common genetic variants have an
important role in the prediction of MI risk. Using increasing
thresholds for the number of SNPs included (based on
ascending p-value), we defined large sets of ‘score alleles’
from the cardiovascular biomarkers [LDL, HDL, apoB,
adiponectin, c-reactive protein (CRP), triglycerides, total
cholesterol] and the MI associated loci to generate aggregate
risk scores. In brief (1), we selected the top N SNPs from each
GWA study on a given lipid trait, avoiding SNPs in strong
linkage disequilibrium (LD) by forcing the SNPs to be at least
100 kb apart (2). For each subject we compiled a risk score
based on his/her genotypes of the selected SNPs. For a SNP
associated with LDL, total cholesterol, apoB or triglycerides, if
the subject was homozygous for a SNP linked to higher lipid
level, we added "+1" to his/her risk score; if homozygous for a
SNP linked to lower lipid level, we added "-1"; a heterozygous
genotype was assigned "0". Signs were reversed for HDL and
adiponectin in the risk score (3). The association of each
subject's risk score to MI was tested in a logistic regression
model and significant results indicated prediction power to MI.
Results
Genome-wide Association for MI and Blood Markers
Cases were matched to controls on age but cases but had a
greater prevalence of hypertension, diabetes and smoking
(Table 1). No loci reached genome-wide thresholds for
statistical significance for MI. Several SNP loci reached
Integrative Genomics of Incident MI in NHS, HPFS
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Figure 1.  SNP set enrichment test work flow.  A: 100 gene sets derived from mRNA profiling signatures, gene expression
networks and other sources relevant to dyslipidemia and cardiovascular disease were assembled. Each gene set was sequentially
tested against the associations identified for the phenotype of interest. For each gene set, multiple eSNPs representing the genes in
that gene set were tested as a group for association to the trait of interest using a Kolmogorov-Smirnov test. B: Gene sets
corresponding to Kegg pathways were also tested for the phenotype of MI.
doi: 10.1371/journal.pone.0085369.g001
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genome wide significance (Table 2) for apoB (rs1713222;
gene: APOB; rs445925; APOE, APOC1), LDL cholesterol
(rs445925; APOE, APOC1), HDL cholesterol (rs3741298;
APOA5, APOA4, APOC3; rs1532625; CETP) and triglycerides
(rs964184; ZNF259, APOA5, APOA4). Notable borderline loci
observed for apolipoprotein B (Table 3) included (rs17765901;
MSRA) and for LDL included (rs563290; APOB) and
(rs12579637; TMEM16D) which was also a suggestive locus
identified for apoB levels.
Loci with suggestive associations for HDL included
(rs1581675, LPL) and (rs11635491; LIPC). Suggestive loci
identified for triglycerides include 8p21 (rs6993414, near LPL),
2p23 (rs780094, near GCKR) and 4q25 (rs7656846, near
PAPSS1).
SNP loci reaching thresholds for genome wide significance
(Table 2) were observed for adiponectin (rs822387, ADIPOQ),
and CRP (rs2027471; CRP and rs4420638; 19q13.32, APOC1,
Table 1. Clinical parameters for the case control cohorts in
the NHS and HPFS.
 HPFS NHS
Characteristic Cases Controls Cases Controls
N 425 878 464 945
Age, years 64.5 (8.6) 64.2 (8.5) 60.2 (6.3) 59.8 (6.3)
Women, % 0% 0% 100% 100%
Hypertension,† % 37.20% 29.00% 50.20% 27.30%
Diabetes,† % 9.00% 3.80% 14.40% 6.24%
Current smoker, % 9.70% 8.70% 27.80% 26.10%
Total cholesterol, mmoL 5.5 (1.0) 5.2 (1.0) 6.1 (1.0) 5.9 (1.0)
HDL cholesterol, mmoL 1.1 (0.3) 1.2 (0.3) 1.3 (0.4) 1.6 (0.4)
Triglyceride, mmoL 1.8 (1.5) 1.5 (2.2) 1.6 (1.0) 1.3 (0.7)
BMI, kg/m2 26.0 (3.2) 25.6 (3.3) 26.0 (6.6) 24.5 (5.8)
Abbreviations: BMI: Body Mass Index; HPFS: Health Professionals follow up study;
NHS: Nurses’ Health Study; N: number of individuals.
† Diabetes and hypertension were based on self-reports of physician diagnoses.
doi: 10.1371/journal.pone.0085369.t001
APOE). No significant loci were identified for creatinine.
Suggestive associations observed for adiponectin levels
included 14q22 (rs8006060, PTGDR, PTGER2) which are
prostaglandin receptors for PGD2 and PGE1 respectively.
Suggestive associations for CRP included the 12q24 locus
(rs7979473; HNF1α).
SNP Set Analysis for MI and apoB
In SSEA analysis, the top gene sets associated with MI
(meta-analysis) included published mRNA profiling signatures
from infarcted tissue (p=2.9E-4), implicated causal genes from
the Global Lipid Genetics GWAS Consortia (p=2.5E-3) (Figure
2), and a gene set formed from the intersection of many gut
profiling signatures in the Nextbio database (p=5.0E-3). Kegg
pathway gene sets significantly associated with MI included
small cell lung cancer (p=1.1E-3), porphyrin and chlorophyll
metabolism (p=1E-2) and glycosaminoglycan degradation
(p=1.6E-2). Finally, for the 29 MI loci previously identified and
replicated by the Myocardial Infarction Genetics, Cardiogram or
the C4D Consortia [9,10,23] no statistically significant individual
SNPs or gene sets were observed.
Gene Environment Interactions Examined for
Myocardial Infarction
SNP interactions that reached or approached genome-wide
levels of significance included rs11147396 with alcohol for MI;
rs3806850 and HDL for MI; rs17542348 with cholesterol for MI
in HPFS only; and rs10794792 with apoB for MI (Table 4).
None of these associations showed a significant association to
MI when examined for main effect in the meta-analysis or in
HPFS only. SNP rs17542348 was marginally associated with
MI risk (p value=3.7E-6) in NHS, where T was the risk allele.
Genotype Risk Score of Cardiovascular Risk Factors
and the Prediction of MI
Not surprisingly, aggregate risk scores derived from
biomarker meta-analysis associations (LDL, HDL, apoB,
adiponectin, CRP) associated strongly with MI in both the
Table 2. SNP associations exceeding thresholds for genome-wide significance.
Trait Snp Allele Maf Location z1(NHS) z2(HPFS) Z(Meta) P value Gene
ApoB rs1713222 G A 0.17 2p24.1 -2.8 -4.8 -5.5 4.25E-08 ApoB
ApoB rs445925 A G 0.14 19q13.32 3.0 4.8 5.6 2.00E-08 ApoE, ApoC1
LDL rs445925 A G 0.14 19q13.32 5.5 4.8 7.1 1.10E-12 ApoE, ApoC1
HDL rs3741298 A G 0.20 11q23.3 -4.5 -4.2 -6.1 8.48E-10 ApoA5, ApoA4, ApoC3
HDL rs1532625 A G 0.44 16q13 -6.0 -5.2 -7.8 6.00E-15 Cetp
Triglycerides rs964184 C G 0.13 11q23.3 4.6 5.4 7.0 2.87E-12 Znf259, ApoA5, ApoA4
Adiponectin rs822387 C T 0.09 3q27.3 -6.3 -0.6 -6.0 1.71E-09 Adipoq
CRP rs2027471 T A 0.34 1q23.2 -4.5 -5.0 -6.7 1.80E-11 Crp
CRP rs440638 A G 0.18 19q13.32 -3.9 -7.2 -8.1 4.44E-16 ApoC1, ApoE
Abbreviations: Allele, Risk Allele & reference allele; ApoB: Apolipoprotein B; CRP: C-reactive protein; location, chromosome location; Gene: nearest gene(s) to associated
SNP; HPFS: health professionals follow- up study; HDL: high density lipoprotein; LDL: low density lipoprotein; MAF, minor allele frequency; Meta: meta-analysis; NHS:
nurses’ health study; rs, Reference SNP; SNP, single nucleotide polymorphism; z1/z2/Z: z-score from individual cohorts and meta-analysis
The p value threshold for genome wide significance in this study was 5x10E-8.
doi: 10.1371/journal.pone.0085369.t002
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HPFS and NHS cohorts individually, with increasing
significance level as the number of SNPs in the score
increased. Scores derived from biomarker associations in
HPFS or NHS did not replicate when tested across gender, and
scores from MI associations did not show strong prediction
across gender (HPFS derived associations tested in NHS).
When scores were derived based on associations from both MI
and biomarker associations analyses in either HPFS or NHS,
moderate levels of association were found for the prediction of
MI across gender with increasing levels of significance
observed as the number of SNPs included in the score
increased. Testing of these risk score paradigms did not
replicate in the Wellcome Trust Case Control Consortium
GWAS for CHD.
Table 3. Suggestive SNP associations for traits of interest.
Trait Snp Allele Maf Location z1(NHS) z2(HPFS) Z(Meta) P value Gene
Myocardial Infraction rs10954357 C T 0.28 7q32.3 3.4 3.2 4.7 2.66E-06 desert, Podxl, Plxna4b
Myocardial Infraction rs7497692 C T 0.22 15q14 3.6 3.0 4.7 3.28E-06 Ryr3
ApoB rs17765901 G T 0.48 8p23.1 1.7 4.7 5.0 6.93E-07 Msra
ApoB rs1347992 A G 0.23 2q24.3 -1.7 -4.6 -4.9 8.90E-07 Scn3a
ApoB rs11110561 C A 0.34 12q23.1 -2.1 -4.3 -4.8 1.62E-06 Tmem16d
ApoB rs3102078 C A 0.35 8p23.1 3.2 3.7 4.8 1.75E-06 Ppp1r3b
ApoB rs10201348 G A 0.14 2q31.2 -2.0 -4.3 -4.7 2.26E-06 Znf533
ApoB rs11569377 T C 0.07 12p13.31 2.3 4.1 4.7 2.50E-06 Cd27
ApoB rs4974961 C T 0.38 4p14 2.1 4.2 4.7 2.81E-06 N4bp2
ApoB rs4915789 A G 0.36 1p31.3 -2.9 -3.8 -4.6 3.33E-06 Inadl
ApoB rs2423066 G A 0.25 20p13 2.4 4.0 4.6 3.42E-06 Slc23a2, Rassf2
ApoB rs11036434 A G 0.33 11p12 -1.4 -4.4 -4.6 4.39E-06 Lrrc4c, Api5
ApoB rs4688296 A T 0.46 3p14.2 -2.9 -3.7 -4.6 4.44E-06 Cadps
HDL rs698739 G T 0.14 8q23.3 -3.5 -3.4 -4.9 1.09E-06 desert, Eif3s3, C8orf53
HDL rs12998922 G C 0.23 2q37.1 -2.2 -4.5 -4.9 1.17E-06 Spp2, Arl4c, Trpm8
HDL rs1581675 A T 0.27 8p21.3 -3.1 -3.6 -4.8 1.55E-06 Lpl
HDL rs13279426 A G 0.11 8p23.2 -4.4 -2.6 -4.8 1.63E-06 Csmd1
HDL rs11635491 A G 0.29 15q22.1 -3.4 -3.4 -4.8 1.78E-06 Lipc
HDL rs10271980 A G 0.40 7q11.22 -2.1 -4.4 -4.8 1.96E-06 desert, Auts2
HDL rs17112078 A G 0.35 14q32.33 3.1 3.6 4.7 2.58E-06 desert, Tmem121, Crip1, Crip2
HDL rs1570513 A G 0.26 9p24.1 -2.9 -3.6 -4.6 4.51E-06 Jmjd2c
LDL rs10963243 A G 0.07 9p22.2 3.6 3.8 5.1 3.20E-07 Sh3gl2
LDL rs563290 A G 0.19 2p24.1 -1.6 -4.5 -4.6 3.43E-06 ApoB
LDL rs711873 G T 0.20 11q13.4 2.6 3.8 4.6 3.89E-06 Slc02b1, Arrb1
LDL rs12579637 A G 0.23 12q23.1 -1.9 -4.2 -4.6 4.39E-06 Tmem16d
TG rs6993414 G A 0.11 8p21.3 4.3 3.0 5.2 2.14E-07 Lpl
TG rs780094 A G 0.40 2p23.3 -4.1 -3.2 -5.1 2.93E-07 Gckr
TG rs6583343 C G 0.45 7p22.3 3.4 3.4 4.8 1.77E-06 Fam20c
TG rs9385770 C T 0.35 6q23.3 -3.8 -3.0 -4.8 1.85E-06 Map3k5
TG rs7656846 A C 0.31 4q25 3.1 3.6 4.7 2.35E-06 Papss1
TG rs9860363 T C 0.07 3q26.1 -3.9 -2.5 -4.6 3.47E-06 desert, Bche
TG rs437895 A G 0.40 8p23.1 3.8 2.6 4.6 4.68E-06 Mfhas1, Cldn23, Thex1
Adiponectin rs8006060 G A 0.14 14q22.1 -4.6 -1.9 -5.0 6.50E-07 Ptgdr, Ptger2
Adiponectin rs6862233 A G 0.28 5q14.1 -4.6 -1.2 -4.7 2.24E-06 Serin5c, Thbs4
Adiponectin rs1606328 C G 0.31 11q22.3 4.2 2.2 4.7 3.14E-06 desert, Gucy1a2, Aasdhppt
Adiponectin rs1514989 C T 0.43 4p15.32 4.3 1.7 4.6 3.57E-06 Ldb2
Adiponectin rs6437640 C G 0.18 3q13.11 -4.3 -1.5 -4.6 4.04E-06 Cblb
Adiponectin rs2270294 G T 0.12 7p14.1 -4.0 -2.5 -4.6 4.50E-06 Amph
CRP rs7979473 G A 0.39 12q24.31 -4.7 -2.9 -5.3 1.08E-07 Tcf1(Hnf1a),C12orf43
Abbreviations: Allele: Risk Allele & reference allele; ApoB: Apolipoprotein B; CRP: C-reactive protein; Gene: nearest gene(s) to associated SNP; HDL: high density
lipoprotein; HPFS: health professionals follow-up study; LDL: low density lipoprotein; location: chromosome location; MAF: minor allele frequency; Meta: meta-analysis of
both cohorts; NHS: Nurses’ health study; rs: reference snp; SNP: single nucleotide polymorphism; z1/z2: meta-analysis z-score; z1/z2/Z: z-score from individual cohorts and
meta- analysis
The p value threshold for genome wide significance in this study was 5x10E-8.
doi: 10.1371/journal.pone.0085369.t003
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Discussion
MI is a leading cause of death and disability worldwide, and
the inherited basis for myocardial infarction remains
incompletely understood, although substantial progress has
been made recently through the application of GWAS
[9,10,23–25]. Applying GWAS to our prospective case-control
studies of MI, we found no loci reaching genome wide
significance levels, and no association signals at 9p21.3 which
has previously been associated with early onset myocardial
infarction or CAD [9,24,25]. Restricting the age of MI to
younger individuals did not elucidate an association signal
around 9p21, although power was even more limited. Similarly,
no strong associations were observed at up to twenty nine
other MI loci previously identified and replicated by the
Myocardial Infarction Genetics, Cardiogram or the C4D
Consortia [9,10,23]. We believe the absence of apparent
association between genetic variants and MI is likely due to
limited sample size. After this study was initiated, it became
apparent the current cohort was substantially underpowered for
the primary endpoint of MI. It is also possible that the
prospective study design influenced the likelihood of detecting
loci discovered predominantly in cross sectional studies.
However larger prospective cohorts will be required to evaluate
this possibility.
Figure 2.  Quantile-Quantile(QQ) plots on SNP set enrichment.  QQ-plots of SNP set enrichment test. Solid line represents
normal distribution and black dots represent data distribution of p-values for eSNPs representing genes within the gene set of
interest. Deviation of the data from the solid line indicates a non-normal distribution. Plots are shown for the top ranking gene sets
A: published mRNA profiling signatures from infarcted tissue and B: implicated causal genes from the Global Lipid Genetics GWAS
Consortium.
doi: 10.1371/journal.pone.0085369.g002
Table 4. Gene: environment and gene: intermediate interactions with incident MI reaching genome-wide significance.
Intxn Chr rsID Study Model 1 Model 2 Model 3 Model 4 Near Gene MI Main Effect p
Alcohol : MI 13q12.3 rs11147396 meta 8.1E-02 1.9E-01 3.0E-09 1.7E-08 Ubl3, Slc7a1 6.7E-01
HDL : MI 5p13.3 rs3806850 meta 2.0E-09 2.6E-08 9.4E-07 3.2E-06 Cdh6 4.3E-01
Chol : MI 7p21.3 rs17542348 HPFS 3.1E-05 2.5E-09 6.6E-04 5.2E-08 Phf14 3.2E-01
ApoB : MI 10p15.3 rs10794792 meta 1.5E-07 3.2E-06 1.3E-08 1.2E-07 Adarb2 (Idl1, Idl2) 9.4E-01
Abbreviations: Chr: chromosome; Intxn: interaction examined; MI: Main Effect; Model: statistical model utilized; Near Gene: nearest gene(s) to associated SNP; p:
association p-value for main effect analysis of Myocardial Infarction; rsID: reference snp identifier; Study: study population meta-analysis of distinct cohort (NHS, HPFS)
a Models 1-4 defined in supporting information (Text S1).
doi: 10.1371/journal.pone.0085369.t004
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Significant SNP associations with blood cholesterol
phenotypes LDL, HDL, apoB and triglycerides were observed,
successfully replicating numerous previous observations
[11,26]. The identification of the APOB locus as the one most
significantly associated with circulating apoB levels confirms
that meaningful information can be derived from GWAS with
quantitative traits using sample sizes in this range. Similarly,
SNPs in close proximity to the gene encoding the C-reactive
protein exhibited the strong associations with CRP levels.
Notable suggestive loci observed for apoB have been
previously associated with adiposity [27] and hypertension [28].
The MSRA locus contains eSNPs for MSRA (MGH subq),
SOX7 (MGH Liver, deLiver) and others [29]. The suggestive
locus around SCN3A is also supported by an expressional
SNP for SCN3A in subcutaneous adipose tissue. FXR (Nr1h4)
is proximal to the TMEM16D locus identified. One of the
primary functions of FXR activation is the suppression of
cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting
enzyme in bile acid synthesis from cholesterol. The N4BP2
locus also contains a (MGH) Liver eSNP to N4BP2 but no
evident biological rationale.
In the context of complex human conditions, the effect size
for a given causal SNP is often very small. Therefore very large
sample size (e.g. N>10,000) would be required to appropriately
power detection of such SNPs. An alternative approach is to
use the SNP Set Enrichment Analysis (SSEA) to determine
whether a group of SNPs, identified by association with gene
sets, is enriched for small p-values in GWAS results by
examining the effect of many SNPs, as a group,
simultaneously. SSEA gains statistical power by (1) reducing
the number of tests and (2) pooling genetic effects from
multiple weak potentially causal SNPs. Many Kegg and
biologically relevant gene sets were assembled and tested
independently, and while the individual SNP p-values were
moderate, as a set, we observed globally significant SSEA p-
values. The top gene sets associated with MI (meta-analysis)
included published mRNA profiling signatures from infarcted
tissue [30], implicated causal genes from the Global Lipid
Genetics Consortia GWAS [11], and a gene set formed from
the intersection of many gut mRNA profiling signatures in the
Nextbio database (www.nextbio.com). The gene signatures
from infarcted tissue were derived in a mouse model of MI and
it is striking that the expression quantitative trait loci for such a
gene set would show a significant association with MI when
examined together. Similarly, expression quantitative trait loci
for genes underlying the Global Lipid Genetics Consortia
GWAS loci show a significant association with MI. This is
perhaps not that surprising given the established relationship in
MI prediction for many of the LDL loci in particular. The gut
mRNA profiling signatures were chosen predominantly on their
relevance to cholesterol related experiments so this may be
reflected in the association identified. Three Kegg pathway
gene sets were significantly associated with MI, but no evident
biological rationale exists for these Kegg pathways. Previously
reported MI GWAS loci only achieve moderate p-values in our
cohorts (partially due to sample size and statistical power).
A number of SNP-environment interactions were observed
that reached or approached genome wide levels of significance
although none of these SNPs were significantly associated with
MI as main effects. The interaction of a locus on 13q12 with
alcohol has not been previously reported in association with MI.
No biological rationale is evident however, for the genes Ubl3
or SLC7A1 that lie in the region of the SNP association. The
gene for Cadherin 6 underlies the interaction observed at 5p13
for HDL in association with MI. Cadherins mediate cell-cell
binding and contribute to the sorting of heterogeneous cell
types and the maintenance of orderly structures in tissue, but
no role has yet been described in lipoprotein metabolism. An
interaction for total cholesterol and a SNP at 7p21 was
observed for MI in the HPFS cohort only. This SNP is near
Phf14, a nuclear phosphoprotein that may function as a colon
cancer tumor suppressor. Finally, an interaction between apoB
and rs10794792 for MI was identified at 10p15 near the gene
location for ADARB2. ADARB2 encodes Adenosine deaminase
RNA-specific B2, which binds to single-stranded and double-
stranded RNAs, and may play a role in regulation of substrate-
specific RNA editing. Hepatic apoB mRNA editing determines
the proportion of VLDL that contains full length (apoB100) or
truncated (apoB48) RNA; however, ADARB2 is not known to
play a role in this process. Additional replication studies are
warranted for these interactions in independent cohorts.
Conclusions
We used prospective case-control studies of MI to illustrate
application of novel SSEA methods and a risk score approach
as a means of assessing groups of loci that may be predictive
of MI, despite marginal individual loci effects. While power
limited our ability to detect significance for individual loci with
MI, we found significance for loci associated with LDL, HDL,
apoB and triglycerides, replicating previous observations.
Applying SSEA and risk score methods, we found significance
for three gene sets and for aggregate scores associated with
MI as well as for loci related to cardiovascular risk factors,
supporting the utility of these methods in practice.
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